Celestial Biolabs Annual Report

Celestial Biolabs Limited (CELESTIAL) Return Comparision with Primex 40 Index

Periods	1 Week	1 Month	3 Months	6 Months	1 Year	3 Years	All Time
Primex-40
Celestial Biolabs Limited

Celestial Biolabs Limited Balance Sheet (In Rs.)

Particulars	31-03-2019	31-03-2018
EQUITY AND LIABILITY
Equity Share Capital	2,258.63	2,258.63
Other equity	7,968.67	7,971.47
Total equity	10,227.30	10,230.10
Non-Current Liabilities
Borrowings	781.65	482.00
Deferred tax liabilities	140.52	-2.65
Current Liabilities
Dues of creditors other than, micro-enterprises and small enterprises	55.79	43.36
other financial liabilities	567.35	470.00
provisions	12.22	17.59
income tax liabilities	148.31	155.05
Total liabilities	1,705.84	1,165.35
TOTAL EQUITY AND LIABILITES	11,933.14	11,395.45
ASSETS
Non-Current Assets
Property plant and equipment	1,215.70	1,284.34
Capital work-in-progress	2,955.81	2,955.81
Other intangible assets	3,935.77	4,025.55
intangible assets under development	1,567.81	488.25
other financial assets		30.10
Current Assets	9,675.09	8,784.05
Inventories	613.50	395.77
Trade receivables	1,563.65	2,076.91
Cash and cash equivalents	5.04	0.99
other current assets	75.85	137.74
Total current assets	2,258.04	2,611.41
TOTAL ASSETS	11,933.13	11,395.45

Celestial Biolabs Limited Profit & Loss Statement (In Rs.)

Particulars	31-03-2019	31-03-2018
Revenue from operations	4,897.42	4,281.46
other income	35.65	0.04
Total revenue	4,933.07	4,281.50
Expenses
cost of material consumed	51.40	10.80
purchase of stock in trade	3,070.24	2,490.61
changes in inventories of finished goods, work-in-progress and stock-in-trade	-251.56	366.59
employee benefits expenses	148.19	63.40
finance costs	125.05	2.54
depreciation and amortisation expenses	944.13	769.54
other expenses	705.27	167.16
total expenses	4,792.72	3,870.64
profit before tax for the year	140.35	410.86
current tax		78.29
differed tax	-143.17	13.06
Total comprehensive income for the years
earning per equity share of face value
basic	-0.01	1.53
diluted	-0.01	1.53

Celestial Biolabs Limited Consolidated Cash Flow Statement (In Rs.)

Particulars	31-03-2019	31-03-2018
CASH FLOW FROM OPERATING ACTIVITY
Net Profit before Tax	140.36	410.86
Depreciation	944.13	769.54
interest and financial charges paid	125.05	2.54
differed tax		13.06
provision for tax		-78.29
Operating Profit before Working Capital Charges	1,209.54	1,117.71
(increase)/decrease in inventory	-217.73	376.00
(increase)/decrease in trade receivables	513.26	-1,251.29
(increase)/decrease in other current assets	61.90
(increase)/decrease in trade payables	12.43	0.98
(increase)/decrease in other financial liabilities	97.63
(increase)/decrease in other current liabilities	-5.37	12.90
(increase)/decrease in provisions	-6.74	77.35
Cash generated from operating activities	1,664.92	333.65
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of fixed assets	-0.26
intangible assets under development	-1,079.56
product development expenses	-785.73	-488.25
Net Cash Flow from Investing Activities	-1,865.55	-488.25
CASH FLOW FROM FINANCING ACTIVITIES
Increase/(Decrease) in borrowings	299.65	-300.00
Increase/(Decrease) in other financial assets	30.10
Increase/(Decrease) in unsecured loans		417.00
interest and financial charges paid	-125.05	-2.54
Net Cash Flow/(used) From Financing Activities	204.70	114.46
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS	4.07	-40.14
CASH & CASD EQUIVALENTS AT THE BEGINNING OF THE YEAR	0.99	41.13
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	5.06	0.99

Herbal supplements Industry Overview

The need for herbal and natural solutions for a range of health issues has led to a strong growth in the Indian herbal supplements market in recent years. At USD 5.26 billion in 2017, the size of the global market for herbal supplements was projected to increase at a compound annual growth rate (CAGR) of 6.2% over the forecast period. A few of the major drivers driving the market expansion include the growing popularity of natural products, increased awareness of preventative healthcare, and rising health and wellness expenditures. The size of the world market for herbal medicines was estimated at $216.40 billion in 2023 and is expected to increase to $437 billion by 2032 from $233.08 billion in 2024. The market for herbal medicines is expected to increase from $233.08 billion to $216.40 billion by 2023.

FAQ Related to the Celestial Biolabs Limited

Q.1 Do Celestial Biolabs Limited is listed or not?

Celestial Biolabs Limited is unlisted company.

Q.2 Is Celestial Biolabs Limited is profitable?

The company has shown an increasing profit and good cash flow statement position.

Q.3 when did Celestial Biolabs Limited gets delisted?

SEBI passed an order to celestial biolabs limited on 5^th of October 2018.

Q.4 What is the main Work of Celestial Biolabs Limited?

Herbal and feed supplement formulations is the main work of celestial biolabs limited.